Value through InnovationMarch 31 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim press releases. To quickly find all press releases on a specific topic, please use the search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10

First-in-class type 2 diabetes treatment Glyxambi® (empagliflozin/linagliptin) tablets for adults now available in U.S. pharmacies


Boehringer Ingelheim’s Investigational Biologic Cleared Skin Better than Ustekinumab in Head-to-Head Phase II Psoriasis Study


New Data from Boehringer Ingelheim’s GLORIATM-AF Registry Show Non-Valvular Atrial Fibrillation (NVAF) Patients at High Risk of Stroke May Be Undertreated


Boehringer Ingelheim Launches The 4Ward Coalition, a Multi-Disciplinary Collaboration Dedicated to Advancing Anticoagulation Care


Boehringer Ingelheim Submits Biologics License Application to FDA for Idarucizumab*, Investigational Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)


New Phase III Data in Asthma Patients Show Tiotropium Improves Lung Function, Regardless of Allergic Status


New Survey Uncovers Emotional and Physical Impact of Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease


Boehringer Ingelheim Launches Groundbreaking Initiative
“Cuida tu Don” with Entertainer “Don Francisco” Aimed at Hispanics with Type 2 Diabetes


U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes


SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the United States

back 1 2 3 4 5 6 7 8 9 10